

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Clark	Examiner:	McIntosh III
Serial No.:	10/828,753	Group Art Unit:	1623
Filed:	April 21, 2004	Docket No.:	60137.0002USU1
Title:	Modified Fluorinated Nucleoside Analogues		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Further to the Information Disclosure Statement filed September 24, 2007, Applicant hereby cites the Stuyver publication (Antiviral Chemistry & Chemotherapy, 2006, 17: 79-87, hereafter "Stuyver") in the present application. Applicant has concurrently filed the requisite fee under 37 CFR 1.17(p).

Stuyver published after the filing date of the present application. Stuyver is directed to a study showing the properties of β -D-2'-deoxy-2'-fluoro-2'-C-methylcytidine with respect to other nucleosides. Applicant believes that consideration of Stuyver might be helpful in understanding the beneficial properties of the compound recited in claim 11.

In the event that Applicant owes a fee that has not yet been paid, Applicant requests that the Office charge any additionally required fees to deposit account no. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300



A handwritten signature in black ink, reading "Daniel R. Evans". The signature is written in a cursive, flowing style.

Daniel R. Evans. Ph.D.
Reg. No. 55,868